Ariela Noy

Oct 13, 2024 | nature.com | Jennifer K Lue |Alexander P Boardman |Steven Horwitz |Andrew M. Intlekofer |Anita Kumar |Ariela Noy | +4 more

Dear Editor,High-grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements (HGBCL-DH/TH) is a group of aggressive lymphomas that are associated with poor outcomes when treated with R-CHOP [1, 2]. Conflicting data exists regarding the outcomes of HGBCL with MYC and BCL2 rearrangements (DH-BCL2) as compared to HGBCL with MYC and BCL6 translocations (DH-BCL6) [3,4,5,6].

Oct 31, 2023 | pericles.pericles-prod.literatumonline.com | Robert Stuver |Ariela Noy |Santosha A. Vardhana |Andrew D Zelenetz

Alison J. Moskowitz Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA Weill Cornell Medical College, New York, New York, USASearch for more papers by this author

Oct 31, 2023 | onlinelibrary.wiley.com | Robert Stuver |Ariela Noy |Santosha A. Vardhana |Andrew D Zelenetz

Alison J. Moskowitz Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA Weill Cornell Medical College, New York, New York, USASearch for more papers by this author